Angiographic biomarkers are significant predictors of treatment response to intravitreal aflibercept in diabetic macular edema
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Angiographic biomarkers are significant predictors of treatment response to intravitreal aflibercept in diabetic macular edema ; volume:13 ; number:1 ; day:19 ; month:5 ; year:2023 ; pages:1-15 ; date:12.2023
Scientific reports ; 13, Heft 1 (19.5.2023), 1-15, 12.2023
- Urheber
-
Hein, Martin
Vukmirovic, Aleksandar
Constable, Ian J.
Raja, Vignesh
Athwal, Arman
Freund, K. Bailey
Balaratnasingam, Chandrakumar
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-35286-2
- URN
-
urn:nbn:de:101:1-2023090911500177656306
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hein, Martin
- Vukmirovic, Aleksandar
- Constable, Ian J.
- Raja, Vignesh
- Athwal, Arman
- Freund, K. Bailey
- Balaratnasingam, Chandrakumar
- SpringerLink (Online service)
Ähnliche Objekte (12)
Changes in metamorphopsia following intravitreal aflibercept injection for diabetic macular edema
Randomized clinical trial comparing intravitreal aflibercept combined with subthreshold laser to intravitreal aflibercept monotherapy for diabetic macular edema
Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema
Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes
Full thickness macular hole case after intravitreal aflibercept treatment
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Correction: Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema
Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME)
Relationship between aqueous humor cytokine level changes and retinal vascular changes after intravitreal aflibercept for diabetic macular edema
Correction to: Intravitreal aflibercept for diabetic macular edema in real‑world clinical practice in Japan: 24‑month outcomes
Retinal Microvasculature and Visual Acuity after Intravitreal Aflibercept in Diabetic Macular Edema: An Optical Coherence Tomography Angiography Study
Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial
Changes in metamorphopsia following intravitreal aflibercept injection for diabetic macular edema
Randomized clinical trial comparing intravitreal aflibercept combined with subthreshold laser to intravitreal aflibercept monotherapy for diabetic macular edema
Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema
Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes
Full thickness macular hole case after intravitreal aflibercept treatment
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Correction: Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema
Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME)
Relationship between aqueous humor cytokine level changes and retinal vascular changes after intravitreal aflibercept for diabetic macular edema
Correction to: Intravitreal aflibercept for diabetic macular edema in real‑world clinical practice in Japan: 24‑month outcomes
Retinal Microvasculature and Visual Acuity after Intravitreal Aflibercept in Diabetic Macular Edema: An Optical Coherence Tomography Angiography Study
Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial
Changes in metamorphopsia following intravitreal aflibercept injection for diabetic macular edema
Randomized clinical trial comparing intravitreal aflibercept combined with subthreshold laser to intravitreal aflibercept monotherapy for diabetic macular edema
Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema
Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes
Full thickness macular hole case after intravitreal aflibercept treatment
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Correction: Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema
Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME)
Relationship between aqueous humor cytokine level changes and retinal vascular changes after intravitreal aflibercept for diabetic macular edema
Correction to: Intravitreal aflibercept for diabetic macular edema in real‑world clinical practice in Japan: 24‑month outcomes
Retinal Microvasculature and Visual Acuity after Intravitreal Aflibercept in Diabetic Macular Edema: An Optical Coherence Tomography Angiography Study